Associations - Conmana (icotinib)

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	icotinib Sensitive: A2 - Guideline icotinib Sensitive : A2	icotinib Sensitive: A2 - Guideline icotinib Sensitive : A2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	bevacizumab + icotinib Sensitive: C2 – Inclusion Criteria bevacizumab + icotinib Sensitive : C2	bevacizumab + icotinib Sensitive: C2 – Inclusion Criteria bevacizumab + icotinib Sensitive : C2
EGFR L858R	Lung Cancer	EGFR L858R	Lung Cancer	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2
EGFR mutation	Lung Cancer	EGFR mutation	Lung Cancer	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2	icotinib Sensitive: C2 – Inclusion Criteria icotinib Sensitive : C2
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
MET amplification	Lung Adenocarcinoma	MET amplification	Lung Adenocarcinoma	erlotinib + gefitinib + icotinib Sensitive: C3 – Early Trials erlotinib + gefitinib + icotinib Sensitive : C3	erlotinib + gefitinib + icotinib Sensitive: C3 – Early Trials erlotinib + gefitinib + icotinib Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
EGFR amplification	Lung Cancer	EGFR amplification	Lung Cancer	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3
TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	icotinib + firmonertinib Sensitive: C3 – Early Trials icotinib + firmonertinib Sensitive : C3	icotinib + firmonertinib Sensitive: C3 – Early Trials icotinib + firmonertinib Sensitive : C3
EGFR K745_E746insIPVAIK	Lung Cancer	EGFR K745_E746insIPVAIK	Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
EGFR L858R	Germ Cell Tumors	EGFR L858R	Germ Cell Tumors	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
EGFR L858R	Germ Cell Tumors	EGFR L858R	Germ Cell Tumors	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
EGFR-RAD51 fusion	Lung Adenocarcinoma	EGFR-RAD51 fusion	Lung Adenocarcinoma	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4
EGFR-SEPTIN14 fusion	Non Small Cell Lung Cancer	EGFR-SEPTIN14 fusion	Non Small Cell Lung Cancer	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4

Conmana (icotinib)

Associations
(45)

Associations
(45)

Conmana (icotinib)

Associations(45)

Associations(45)

Associations
(45)

Associations
(45)